C/EBPβ is detected in normal liver tissue but its protein levels or transcriptional activity decrease during various hepatic disease, including thioacetamide (a drug widely used for induction of fibrosis and acute liver failure)- or dimethylnitrosamine (DEN, a drug used to induce liver cirrhosis in experimental animals)-induced liver fibrosis, methionine-, and choline-deficient diet (MCD, used to induce nonalcoholic fatty liver disease)-induced liver fibrosis, CCl4-induced liver fibrosis, and streptozotocin (a drug can damage pancreatic beta insular cells)-induced diabetes [103, 144–147]. The gene discussed is CEBPB; the disease is Hepatic fibrosis.